Puma Biotechnology Inc. (PBYI)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.
Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript
Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript
Puma Biotechnology Q2 Earnings Call Highlights
Puma Biotechnology NASDAQ: PBYI reported second-quarter 2026 total revenue of $56.5 million, including $53.6 million in net product revenue from NERLYNX and $2.9 million in royalty revenue. The company posted GAAP net income of $8.2 million, or $0.16 per diluted share, compared with a net loss of $3.8 million, or $0.07 per share, in the first quarter.
Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates
Puma Biotech (PBYI) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.15 per share a year ago.
Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why
PBYI's shares rally 19% in three months as rising Nerlynx demand and a raised 2026 revenue outlook boost investor confidence.
Puma Biotechnology Q1 Earnings Call Highlights
Puma Biotechnology NASDAQ: PBYI reported first-quarter 2026 total revenue of $44.8 million, driven primarily by NERLYNX product revenue net of $42.0 million and royalty revenue of $2.8 million, according to remarks on the company's earnings call. Management attributed the quarter's product revenue performance in part to a specialty pharmacy and distributor inventory drawdown and highlighted new interim clinical data from ongoing Phase II alisertib studies in small cell lung cancer and HER2-negative, hormone receptor-positive breast cancer.
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology beats Q1 earnings and revenue estimates while raising its 2026 outlook.
Puma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call Transcript
Puma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call Transcript
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
Puma Biotech (PBYI) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to earnings of $0.1 per share a year ago.
Gun Makers Reach Cooperation Pact After Months of Tense Proxy Battle
Under the terms of their new agreement, Beretta may increase its investment in Sturm, Ruger to up to 25% of outstanding shares, including a tender offer at a minimum of $44.80 a share.
